Search
From Promising Science to Patient Care
We apply our science to discover and develop first-in-class or best-in-class medicines with the goal of creating transformational anti-cancer therapeutics. We conduct clinical trials to help confirm that our medicines offer genuine benefit, while balancing the risk of side effects. It’s part of our commitment to advance novel therapeutics and make a meaningful difference in the lives of people with cancer.
We’re committed to sharing information from completed clinical trials through public registries, scientific literature, and presentations. If you’d like additional information about one of our trials, please submit a request.
Brentuximab Vedotin
Study
Therapeutic Area(s)
Phase
Recruiting Status
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Learn More
Diffuse Large B-cell Lymphoma
Phase 3
Recruiting
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Learn More
Hodgkin Lymphoma
Phase 2
Recruiting
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment Learn More
Hodgkin Disease
Phase 2
Recruiting
Enfortumab Vedotin
Study
Therapeutic Area(s)
Phase
Recruiting Status
A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Learn More
Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2
Recruiting
Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherapy, vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302) Learn More
Urothelial Cancer
Phase 3
Recruiting
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) Learn More
Urinary Bladder Cancer, Muscle-invasive
Phase 3
Recruiting
Ladiratuzumab Vedotin
Study
Therapeutic Area(s)
Phase
Recruiting Status
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Learn More
Small Cell Lung Cancer,
Non-small Cell Lung Cancer, Squamous,
Non-small Cell Lung Cancer, Non-squamous,
Head and Neck Squamous Cell Carcinoma,
Esophageal Squamous Cell Carcinoma,
Gastric Adenocarcinoma,
Gastroesophageal Junction Adenocarcinoma
Phase 2
Recruiting
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer Learn More
Breast Neoplasms
Phase 1,
Phase 2
Recruiting
A Safety Study of SGN-LIV1A in Breast Cancer Patients Learn More
Breast Cancer
Phase 1
Recruiting
Tisotumab Vedotin
Study
Therapeutic Area(s)
Phase
Recruiting Status
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) Learn More
Ovarian Cancer,
Fallopian Tube Cancer,
Peritoneal Cancer
Phase 2
Recruiting
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Learn More
Colorectal Neoplasms,
Carcinoma, Non-Small-Cell Lung,
Exocrine Pancreatic Cancer,
Carcinoma, Squamous Cell of Head and Neck
Phase 2
Recruiting
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer Learn More
Cervical Cancer
Phase 1,
Phase 2
Recruiting
Tucatinib
Study
Therapeutic Area(s)
Phase
Recruiting Status
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers Learn More
Colorectal Carcinoma,
Gastric Adenocarcinoma,
Esophageal and GEJ Adenocarcinoma,
Cholangiocarcinoma,
Gallbladder Carcinoma
Phase 1
Recruiting
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer Learn More
HER2-positive Breast Cancer
Phase 3
Recruiting
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Learn More
Metastatic Colorectal Adenocarcinoma
Phase 2
Recruiting
SEA-BCMA
Study
Therapeutic Area(s)
Phase
Recruiting Status
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma Learn More
Multiple Myeloma
Phase 1
Recruiting
SEA-CD40
Study
Therapeutic Area(s)
Phase
Recruiting Status
Safety Study of SEA-CD40 in Cancer Patients Learn More
Cancer,
Carcinoma,
Carcinoma, Non-Small-Cell Lung,
Carcinoma, Squamous Cell,
Hematologic Malignancies,
Hodgkin Disease,
Lymphoma,
Lymphoma, B-Cell,
Lymphoma, Follicular,
Lymphoma, Large B-Cell, Diffuse,
Melanoma,
Neoplasms,
Neoplasm Metastasis,
Neoplasms, Head and Neck,
Neoplasms, Squamous Cell,
Non-Small Cell Lung Cancer,
Non-Small Cell Lung Cancer Metastatic,
Non-small Cell Carcinoma,
Squamous Cell Cancer,
Squamous Cell Carcinoma,
Squamous Cell Carcinoma of the Head and Neck,
Squamous Cell Neoplasm,
Lymphoma, Non-Hodgkin,
Pancreatic Adenocarcinoma
Phase 1
Recruiting
SEA-CD70
Study
Therapeutic Area(s)
Phase
Recruiting Status
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies Learn More
Myelodyspastic Syndrome,
Acute Myeloid Leukemia
Phase 1
Recruiting
SGN-TGT
Study
Therapeutic Area(s)
Phase
Recruiting Status
A Safety Study of SGN-TGT (SEA-TGT) in Patients With Advanced Cancer Learn More
Non-small Cell Lung Cancer,
Gastric Carcinoma,
Classical Hodgkin Lymphoma,
Diffuse Large B-cell Lymphoma,
Peripheral T-cell Lymphoma
Phase 1
Recruiting
SGN-B6A
Study
Therapeutic Area(s)
Phase
Recruiting Status
A Study of SGN-B6A in Advanced Solid Tumors Learn More
Non-small Cell Lung Cancer,
Head and Neck Squamous Cell Cancer,
Breast Cancer,
Esophageal Cancer,
Ovarian Cancer,
Cutaneous Squamous Cell Cancer,
Exocrine Pancreatic Adenocarcinoma,
Bladder Cancer,
Cervical Cancer,
Gastric Cancer
Phase 1
Recruiting
SGN-CD228A
Study
Therapeutic Area(s)
Phase
Recruiting Status
A Study of SGN-CD228A in Advanced Solid Tumors Learn More
Cutaneous Melanoma,
Pleural Mesothelioma,
Breast Cancer,
Non-small Cell Lung Cancer,
Colorectal Cancer,
Pancreatic Ductal Adenocarcinoma
Phase 1
Recruiting
Considering a clinical trial? Learn more about the possible benefits and risks, what to expect, and how to find out if you’re eligible.
Request additional information about an investigational therapy.